Lincoln Pharmaceuticals Limited (LINCOLN.NS)
INR 552.6
(3.05%)
INR 552.6
(3.05%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 5.8 Billion INR | 13.76% |
| 2022 | 5.1 Billion INR | 8.99% |
| 2021 | 4.68 Billion INR | 12.89% |
| 2020 | 4.14 Billion INR | 10.06% |
| 2019 | 3.76 Billion INR | 5.58% |
| 2018 | 3.56 Billion INR | 0.54% |
| 2017 | 3.54 Billion INR | -1.56% |
| 2016 | 3.6 Billion INR | -9.87% |
| 2015 | 4 Billion INR | 50.39% |
| 2014 | 2.66 Billion INR | 25.94% |
| 2013 | 2.11 Billion INR | 9.53% |
| 2012 | 1.92 Billion INR | 9.93% |
| 2011 | 1.75 Billion INR | -3.96% |
| 2010 | 1.82 Billion INR | 44.16% |
| 2009 | 1.26 Billion INR | 10.74% |
| 2008 | 1.14 Billion INR | 32.71% |
| 2007 | 862.31 Million INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.47 Billion INR | 3.36% |
| 2023 Q4 | 1.42 Billion INR | -2.7% |
| 2023 FY | 5.8 Billion INR | 13.76% |
| 2023 Q1 | 1.35 Billion INR | 20.59% |
| 2023 Q2 | 1.55 Billion INR | 15.02% |
| 2023 Q3 | 1.46 Billion INR | -6.11% |
| 2022 Q2 | 1.4 Billion INR | 13.88% |
| 2022 Q3 | 1.33 Billion INR | -4.87% |
| 2022 Q4 | 1.12 Billion INR | -15.93% |
| 2022 Q1 | 1.23 Billion INR | 25.15% |
| 2022 FY | 5.1 Billion INR | 8.99% |
| 2021 Q4 | 986.6 Million INR | -17.7% |
| 2021 FY | 4.68 Billion INR | 12.89% |
| 2021 Q1 | 1.22 Billion INR | 74.2% |
| 2021 Q2 | 1.27 Billion INR | 4.32% |
| 2021 Q3 | 1.19 Billion INR | -5.95% |
| 2020 Q3 | 1.14 Billion INR | -8.98% |
| 2020 Q2 | 1.26 Billion INR | 21.46% |
| 2020 Q1 | 1.03 Billion INR | 50.83% |
| 2020 Q4 | 701.42 Million INR | -38.87% |
| 2020 FY | 4.14 Billion INR | 10.06% |
| 2019 Q3 | 985.23 Million INR | -12.57% |
| 2019 Q4 | 688.16 Million INR | -30.15% |
| 2019 FY | 3.76 Billion INR | 5.58% |
| 2019 Q1 | 968.12 Million INR | 38.19% |
| 2019 Q2 | 1.12 Billion INR | 16.4% |
| 2018 Q1 | 998.21 Million INR | 48.25% |
| 2018 Q4 | 700.59 Million INR | -17.03% |
| 2018 Q2 | 1.02 Billion INR | 2.79% |
| 2018 Q3 | 844.34 Million INR | -17.71% |
| 2018 FY | 3.56 Billion INR | 0.54% |
| 2017 Q3 | 801.84 Million INR | -10.56% |
| 2017 FY | 3.54 Billion INR | -1.56% |
| 2017 Q4 | 673.35 Million INR | -16.02% |
| 2017 Q2 | 896.54 Million INR | -33.52% |
| 2017 Q1 | 1.34 Billion INR | 13.31% |
| 2016 FY | 3.6 Billion INR | -9.87% |
| 2016 Q3 | 735.48 Million INR | -5.3% |
| 2016 Q2 | 776.61 Million INR | -12.9% |
| 2016 Q1 | 891.62 Million INR | -25.69% |
| 2016 Q4 | 1.19 Billion INR | 61.82% |
| 2015 Q3 | 1.04 Billion INR | 14.65% |
| 2015 Q1 | 732.34 Million INR | -6.94% |
| 2015 FY | 4 Billion INR | 50.39% |
| 2015 Q2 | 911.59 Million INR | 24.48% |
| 2015 Q4 | 1.19 Billion INR | 14.8% |
| 2014 Q2 | 759.1 Million INR | 61.69% |
| 2014 Q4 | 786.98 Million INR | 21.98% |
| 2014 Q3 | 645.15 Million INR | -15.01% |
| 2014 Q1 | 469.49 Million INR | -29.89% |
| 2014 FY | 2.66 Billion INR | 25.94% |
| 2013 Q3 | 519.94 Million INR | -4.33% |
| 2013 Q1 | 379.53 Million INR | -33.17% |
| 2013 Q2 | 543.49 Million INR | 43.2% |
| 2013 Q4 | 669.69 Million INR | 28.8% |
| 2013 FY | 2.11 Billion INR | 9.53% |
| 2012 Q4 | 567.94 Million INR | 11.15% |
| 2012 Q3 | 510.99 Million INR | -7.83% |
| 2012 Q2 | 554.39 Million INR | 87.64% |
| 2012 Q1 | 295.44 Million INR | -18.09% |
| 2012 FY | 1.92 Billion INR | 9.93% |
| 2011 Q3 | 545.29 Million INR | 0.0% |
| 2011 FY | 1.75 Billion INR | -3.96% |
| 2011 Q4 | 360.7 Million INR | -33.85% |
| 2010 FY | 1.82 Billion INR | 44.16% |
| 2009 FY | 1.26 Billion INR | 10.74% |
| 2008 FY | 1.14 Billion INR | 32.71% |
| 2008 Q4 | 217.47 Million INR | 0.0% |
| 2007 FY | 862.31 Million INR | 0.0% |
| 2007 Q4 | 260.44 Million INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 90.502% |
| Hester Biosciences Limited | 3.04 Billion INR | -90.628% |
| Aarti Drugs Limited | 25.28 Billion INR | 77.04% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 68.023% |
| Albert David Limited | 3.62 Billion INR | -60.169% |
| Alembic Limited | 1.57 Billion INR | -268.637% |
| Alkem Laboratories Limited | 126.67 Billion INR | 95.417% |
| Bafna Pharmaceuticals Limited | 1.52 Billion INR | -280.774% |
| Bajaj HealthCare Limited | 4.73 Billion INR | -22.629% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -1350.094% |
| Brooks Laboratories Limited | 794.86 Million INR | -630.379% |
| Eris Lifesciences Limited | 20.09 Billion INR | 71.105% |
| FDC Limited | 19.42 Billion INR | 70.12% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 74.573% |
| Gufic Biosciences Limited | 8.06 Billion INR | 28.031% |
| Hikal Limited | 17.84 Billion INR | 67.469% |
| Ind-Swift Limited | 5.02 Billion INR | -15.54% |
| Innova Captab Limited | 10.81 Billion INR | 46.31% |
| IOL Chemicals and Pharmaceuticals Limited | 21.32 Billion INR | 72.78% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -178.172% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 91.339% |
| Lupin Limited | 196.56 Billion INR | 97.047% |
| Mangalam Drugs & Organics Limited | 3.67 Billion INR | -58.036% |
| Medico Remedies Limited | 1.44 Billion INR | -300.598% |
| Morepen Laboratories Limited | 17.01 Billion INR | 65.888% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 65.537% |
| Orchid Pharma Limited | 8.19 Billion INR | 29.147% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 49.573% |
| RPG Life Sciences Limited | 5.82 Billion INR | 0.258% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -276.071% |
| Sigachi Industries Limited | 3.98 Billion INR | -45.517% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 53.121% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 44.781% |
| Themis Medicare Limited | 3.81 Billion INR | -52.072% |
| Unichem Laboratories Limited | 16.57 Billion INR | 64.973% |
| Vaishali Pharma Limited | 862.79 Million INR | -572.869% |
| Wanbury Limited | 5.75 Billion INR | -0.851% |
| Windlas Biotech Limited | 6.3 Billion INR | 7.989% |
| ZIM Laboratories Limited | 3.67 Billion INR | -57.965% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 54.676% |
| Ipca Laboratories Limited | 77.05 Billion INR | 92.466% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 98.803% |
| Venus Remedies Limited | 5.91 Billion INR | 1.843% |
| Sakar Healthcare Limited | 1.54 Billion INR | -276.571% |
| Aurobindo Pharma Limited | 290.01 Billion INR | 97.998% |
| Divi's Laboratories Limited | 78.45 Billion INR | 92.6% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 55.188% |
| Mankind Pharma Limited | 103.34 Billion INR | 94.383% |
| Sequent Scientific Limited | 13.69 Billion INR | 57.616% |
| Laurus Labs Limited | 50.01 Billion INR | 88.393% |
| Neuland Laboratories Limited | 15.58 Billion INR | 62.751% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.47 Billion INR | 83.161% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 95.086% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 96.948% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -37.822% |
| Wockhardt Limited | 27.89 Billion INR | 79.184% |
| Bal Pharma Limited | 3.39 Billion INR | -71.143% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 97.92% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 24.628% |
| Par Drugs and Chemicals Limited | 956.4 Million INR | -507.013% |
| Caplin Point Laboratories Limited | 16.76 Billion INR | 65.377% |
| Shilpa Medicare Limited | 11.53 Billion INR | 49.653% |
| Valiant Laboratories Limited | 1.82 Billion INR | -218.883% |
| Ajanta Pharma Limited | 42.08 Billion INR | 86.206% |
| Aarey Drugs & Pharmaceuticals Limited | 3.95 Billion INR | -46.745% |
| Granules India Limited | 45.06 Billion INR | 87.117% |
| Medicamen Biotech Limited | 1.79 Billion INR | -223.776% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -123.939% |
| Piramal Enterprises Limited | 60.33 Billion INR | 90.378% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 94.526% |
| NATCO Pharma Limited | 40.02 Billion INR | 85.494% |
| Suven Life Sciences Limited | 116.92 Million INR | -4864.975% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -1051.393% |
| Strides Pharma Science Limited | 40.51 Billion INR | 85.669% |
| Indoco Remedies Limited | 18.17 Billion INR | 68.054% |
| Alpa Laboratories Limited | 1.08 Billion INR | -433.893% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -456.428% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -668.479% |